BACKGROUND: Few data are available on the use of statins after publication of the National Cholesterol Education Program Third Adult Treatment Panel (ATP-III) guidelines in 2001. OBJECTIVE: To determine changes in statin use and its impact on low-density lipoprotein cholesterol (LDL-C) control among US adults from 1999 to 2004. METHODS: High LDL-C levels and statin use among 1911 participants of the National Health and Nutrition Examination Survey (NHANES) 2003-2004 were determined and compared with 1770 and 2094 participants of NHANES 1999-2000 and NHANES 2001-2002, respectively. Statin use was obtained from review of participants' drug containers. High LDL-C levels and LDL-C control were defined, using risk-specific cut-points from the ATP-III guidelines. RESULTS: Statins were taken by 24 million Americans in 2003-2004, an increase from 12.5 million in 1999-2000. In 1999-2000, 2001-2002, and 2003-2004, statins were being used by 19.6%, 27.3%, and 35.9% of US adults with high LDL-C levels, respectively (p trend <0.001). Age-standardized mean LDL-C declined from 119.9 to 112.0 to 100.7 mg/dL among statin users between 1999-2000, 2001-2002, and 2003-2004. LDL-C control to ATP-III recommended targets was achieved by 49.7%, 67.4%, and 77.6% of statin users in 1999-2000, 2001-2002, and 2003-2004, respectively (p trend <0.001). Among US adults with high LDL-C, after multivariate adjustment, non-Hispanic blacks were 39% less likely (prevalence ratio = 0.61; 95 CI 0.39 to 0.97) than non-Hispanic whites to be taking statins. CONCLUSIONS: Statin use continues to increase among US adults and this has led to substantial improvements in LDL-C control. Nevertheless, suboptimal statin use, especially among racial/ethnic minorities, continues to prevent the maximal public health benefit from this effective drug class.
BACKGROUND: Few data are available on the use of statins after publication of the National Cholesterol Education Program Third Adult Treatment Panel (ATP-III) guidelines in 2001. OBJECTIVE: To determine changes in statin use and its impact on low-density lipoprotein cholesterol (LDL-C) control among US adults from 1999 to 2004. METHODS: High LDL-C levels and statin use among 1911 participants of the National Health and Nutrition Examination Survey (NHANES) 2003-2004 were determined and compared with 1770 and 2094 participants of NHANES 1999-2000 and NHANES 2001-2002, respectively. Statin use was obtained from review of participants' drug containers. High LDL-C levels and LDL-C control were defined, using risk-specific cut-points from the ATP-III guidelines. RESULTS: Statins were taken by 24 million Americans in 2003-2004, an increase from 12.5 million in 1999-2000. In 1999-2000, 2001-2002, and 2003-2004, statins were being used by 19.6%, 27.3%, and 35.9% of US adults with high LDL-C levels, respectively (p trend <0.001). Age-standardized mean LDL-C declined from 119.9 to 112.0 to 100.7 mg/dL among statin users between 1999-2000, 2001-2002, and 2003-2004. LDL-C control to ATP-III recommended targets was achieved by 49.7%, 67.4%, and 77.6% of statin users in 1999-2000, 2001-2002, and 2003-2004, respectively (p trend <0.001). Among US adults with high LDL-C, after multivariate adjustment, non-Hispanic blacks were 39% less likely (prevalence ratio = 0.61; 95 CI 0.39 to 0.97) than non-Hispanic whites to be taking statins. CONCLUSIONS: Statin use continues to increase among US adults and this has led to substantial improvements in LDL-C control. Nevertheless, suboptimal statin use, especially among racial/ethnic minorities, continues to prevent the maximal public health benefit from this effective drug class.
Authors: Bradley W Blaser; Haesook T Kim; Edwin P Alyea; Vincent T Ho; Corey Cutler; Philippe Armand; John Koreth; Joseph H Antin; Jorge Plutzky; Robert J Soiffer Journal: Biol Blood Marrow Transplant Date: 2011-08-11 Impact factor: 5.742
Authors: Robyn L McClelland; Neal W Jorgensen; Wendy S Post; Moyses Szklo; Richard A Kronmal Journal: Pharmacoepidemiol Drug Saf Date: 2013-02-04 Impact factor: 2.890
Authors: Yun Wang; Judith H Lichtman; Kumar Dharmarajan; Frederick A Masoudi; Joseph S Ross; John A Dodson; Jersey Chen; John A Spertus; Sarwat I Chaudhry; Brahmajee K Nallamothu; Harlan M Krumholz Journal: Am Heart J Date: 2014-06-14 Impact factor: 4.749
Authors: Grzegorz S Nowakowski; Matthew J Maurer; Thomas M Habermann; Stephen M Ansell; William R Macon; Kay M Ristow; Cristine Allmer; Susan L Slager; Thomas E Witzig; James R Cerhan Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: Kristi Reynolds; Alan S Go; Thomas K Leong; Denise M Boudreau; Andrea E Cassidy-Bushrow; Stephen P Fortmann; Robert J Goldberg; Jerry H Gurwitz; David J Magid; Karen L Margolis; Catherine J McNeal; Katherine M Newton; Rachel Novotny; Charles P Quesenberry; Wayne D Rosamond; David H Smith; Jeffrey J VanWormer; Suma Vupputuri; Stephen C Waring; Marc S Williams; Stephen Sidney Journal: Am J Med Date: 2016-10-14 Impact factor: 4.965